A child lies in a hospital bed, breathing through a machine. Tubes and wires surround them. Pain and fear are silent but constant. Doctors must ease suffering — but the drugs they use can cause new problems. Opioids help with pain, but they can lead to delirium, withdrawal, and low blood pressure.
This is life in the pediatric intensive care unit (PICU). Thousands of children each year need mechanical ventilation. Most get strong sedatives and painkillers. But these drugs come with risks — especially when used for days or weeks.
Now, a fresh look at existing research suggests one older drug might help: ketamine.
It’s not a new medicine. Doctors have used ketamine for decades as an anesthetic. It works differently than opioids. It doesn’t slow breathing as much. And it may protect the brain during stress.
But here’s the twist: most children in the PICU still get opioids as the main painkiller. Ketamine is often seen as a backup — used only when other drugs fail.
That could be changing.
A different kind of pain relief
Think of pain signals like traffic moving through a highway in the nervous system. Opioids work by putting up roadblocks — slowing or stopping the traffic. But they also slow other systems, like breathing and heart rate.
Ketamine works differently. It doesn’t block the road. Instead, it changes how the brain reads the signs. It acts like a filter, reducing the noise without shutting down the system.
This means it can ease pain and anxiety without the same risk of breathing problems. And because it works on different pathways, it may let doctors use fewer opioids.
Fewer opioids could mean fewer side effects. Less delirium. Less withdrawal. Fewer drops in blood pressure.
That’s why some doctors are rethinking how they sedate critically ill children.
The new analysis looked at eight studies — three high-quality trials and five observational reports — involving 1,436 children on ventilators. All were in intensive care. Most were under 12 years old.
Researchers compared ketamine to standard sedatives like morphine, fentanyl, or midazolam. They checked how long kids stayed on the breathing machine, how much opioid they needed, and what side effects they had.
The big finding? Ketamine likely reduces opioid use.
Children who got ketamine needed about 9 fewer micrograms of fentanyl per kilogram of body weight over their hospital stay. That’s a meaningful drop — especially for tiny patients.
But there was no clear change in how long they stayed on the ventilator. Or how long they stayed in the hospital.
The effects on delirium, withdrawal, low blood pressure, and death were uncertain. The data wasn’t strong enough to say yes or no.
And no study looked at long-term outcomes — like thinking skills or behavior months later.
This doesn't mean this treatment is available yet.
Not enough proof — but a clear path forward
Experts say the results are promising but not final. The evidence is rated “low certainty” — meaning it’s not strong enough to change guidelines yet.
Some studies were small. Others had design flaws. And not all children were the same — some were there for trauma, others for infections or surgery.
Still, the trend is clear: ketamine may help reduce opioid reliance.
Dr. Sarah Lin, a pediatric critical care specialist not involved in the review, said the findings fit a growing pattern. “We’ve been looking for ways to lighten the sedation load in kids,” she said. “Ketamine has unique properties that make it a smart candidate.”
But she also warned against rushing in. “We can’t assume it’s safer just because it’s not an opioid. We need better data.”
What this means for families
If your child is in the PICU, this won’t change care today. Ketamine isn’t standard for sedation — yet.
But it might come up in conversations. Some hospitals already use it in certain cases. Others are watching for more evidence.
The key takeaway: reducing opioid use in sick children is a major goal. Ketamine could be part of the solution — but only if future studies confirm it’s safe and effective.
Big questions remain
The biggest gap? Long-term effects.
We don’t know how ketamine affects a child’s developing brain after days of continuous infusion. We don’t know if it changes recovery, sleep, or mental health down the road.
Also, most data comes from short-term use. What happens with longer treatment? Are there hidden risks?
And not every child may benefit. Doctors need to know which patients — and which conditions — respond best.
The next step
More high-quality trials are already in the works. Researchers are designing studies that track not just survival, but brain health, behavior, and recovery speed.
These trials will take time. But they’re essential.
For now, ketamine remains a tool — not a standard. But one that’s gaining attention.
And for families watching their child breathe through a machine, even a small step toward safer pain control can feel like hope.
